诱导化疗期间行微小残留白血病检测在急性髓系白血病预后判断中的价值  

Value of minimal residual disease detection during induction chemotherapy on prognosis of acute myeloid leukemia

作　　者：张静[1] 孙玲[1] 孟小莉[1] 桑丽娜[1] 闫春艳[1] 

机构地区：[1]郑州大学第一附属医院血液科,450052

出　　处：《中国实用医刊》2014年第13期65-66,共2页Chinese Journal of Practical Medicine

摘　　要：目的分析急性髓系白血病（AML）患者诱导缓解化疗第7天微小残留白血病（MRD）检测与预后的关系。方法采用多参数流式细胞分析术对45例原发、初治成人AML患者于诱导缓解化疗第7天行MRD检测。结果化疗第7天MRD〈10—2患者1个疗程完全缓解（CR）率明显高于MRD〉10—2组患者（分别为85．7％和58．3％，P〈0．05，差异有统计学意义）；对于化疗第7天MRD〉10—2者，适当延长化疗时间可提高1个疗程CR率（缓解率分,51J为66．7％和55．6％），但两者相比差异无统计学意义（P〉0．05）。结论于诱导缓解化疗第7天行MRD检测有助于AML预后的评估，同时为是否延长化疗时间提供依据。Objective To analyze the relationship between minimal residual disease（MRD） de- tection in AML patients on seventh day of induction chemotherapy and prognosis. Methods The MRD was detected by multi-parameter flow cytometry in 45 cases of primary, newly diagnosed adult AML on seventh day of remission induction chemotherapy. Results Complete remission （CR） rate after the first course in MRD 〈 10-2 group was significantly higher than that in MRD 〉 10-2 group （ 85.7% and 58.3%, respectively, P 〈 0. 05, the difference had statistically significance） ; For patients in MRD 〉 10- 2 group, prolonged the chemotherapy course for a few more days could improve the CR rate （remission rates were 66.7% and 55.6%, but the difference was not statistically significant（ ,P 〉 0. 05 ）. Conclu- sions Detection of MRD on seventh day of remission induction chemotherapy in AML is helpful in pre- dicting the prognosis, as well as providing the basis for prolonging chemotherapy.

关 键 词：急性髓系白血病 微小残留白血病检测 完全缓解率 

分 类 号：R733.7[医药卫生—肿瘤]